Health care startups in Shanghai, China
Updated 16 Nov 2026
Not sure about the data?
Download a free 10-row sample first. No account, no payment.
| Company | City | Last round | Amount | Date |
|---|---|---|---|---|
| Enjosim | Shanghai | Series B | $30.1M | 2026-11-02 |
| Degron Therapeutics | Shanghai | Series A | $40.0M | 2026-05-14 |
| MindRank AI | Shanghai | Series B | $52.0M | 2026-07-08 |
| Bluesail Surgical | Shanghai | Series B | $104.5M | 2026-09-23 |
| Full-Life Technologies | Shanghai | Series D | $109.0M | 2026-05-18 |
| Nutshell Therapeutics | Shanghai | Series C | $40.0M | 2026-09-15 |
| Phrontline Biopharma | Shanghai | Seed | $60.0M | 2025-11-21 |
| Bivision | Shanghai | Series B | $58.8M | 2026-05-18 |
8 rows of the CSV in 5 of its 18 columns.
- The 447 health care startups in Shanghai, China have raised $12.1B in total.
- 70 of them closed their most recent round in the last 12 months, $1.8B combined.
- The largest of those rounds is CORXEL Pharmaceuticals' $287.0M Series D, dated January 2026.
- The most recent is Shanghai Peptide Biotechnology's $140K seed round on 10 November 2026.
- Sherpa Healthcare Partners is an investor in 7 of them, more than any other fund.
- Biotech is the most common other sector, with 194 companies (43%).
- 28% were founded in 2020 or later; the median founding year is 2016.
- The most common team size is 11 to 50 employees (35% of companies with a recorded size).
Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.
Newest rounds
15 of 447| Company | What they do | Sector | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|
| Enjosim | Enjosim researches, manufactures, and sells self-delivery systems for biomacromolecule pharmaceuticals. | Biotech | Series B | $30.1M | 2026-11-02 | $30.1M | Luminous Ventures (former Lightspeed China Partners), Jiayuan Capital | 51 to 100 | 2021 |
| Bluesail Surgical | Bluesail Surgical develops surgical instruments for cardiovascular treatments. | Biotech | Series B | $104.5M | 2026-09-23 | $245.4M | Huagai Capital, Linkong Private Equity Fund Management, Linqu County High-Tech Industrial Investment | 101 to 250 | 2020 |
| Nutshell Therapeutics | Nutshell Therapeutics discovers small-molecule drugs using insights from protein dynamics. | Artificial intelligence | Series C | $40.0M | 2026-09-15 | $75.2M | Matrix Partners China, Source Code Capital, Northern Light Venture Capital +1 | 51 to 100 | 2013 |
| MindRank AI | MindRank AI develops artificial intelligence platforms to discover and develop small molecule drugs. | Artificial intelligence | Series B | $52.0M | 2026-07-08 | $101.0M | Green Pine Capital Partners, Huagai Capital, Sherpa Healthcare Partners +1 | 11 to 50 | 2020 |
| Full-Life Technologies | Full-Life Technologies develops, produces, and commercializes medicines for cancer therapy. | Biotech | Series D | $109.0M | 2026-05-18 | $337.3M | Sky9 Capital, Chengwei Capital, Prosperity7 Ventures +1 | 51 to 100 | 2021 |
| Bivision | Bivision researches and develops targeted radiopharmaceuticals for therapy. | Biotech | Series B | $58.8M | 2026-05-18 | $100.9M | Gaorong Capital, Kaitai Capital, Lichen Capital | 11 to 50 | 2021 |
| Degron Therapeutics | Degron Therapeutics discovers molecular glue degraders for cancer treatment. | Biotech | Series A | $40.0M | 2026-05-14 | $94.0M | Baidu Ventures, BioVenture, New Alliance Capital +2 | 101 to 250 | 2021 |
| Novamab | Novamab researches and develops new nanobodies. | Biotech | Series B | $43.9M | 2026-04-24 | $97.8M | Qiming Venture Partners, Taiyu Investment, Fuho Capital +1 | 51 to 100 | 2017 |
| CORXEL Pharmaceuticals | CORXEL Pharmaceuticals develops medicines for underserved patients. | Biotech | Series D | $287.0M | 2026-01-22 | $451.8M | Leaps by Bayer, RTW Investments | 51 to 100 | 2019 |
| Alioth | Alioth develops and applies technical products for pharmaceutical process technology. | Biotech | Series B | $14.4M | 2026-01-15 | $54.7M | Matrix Partners China, Legend Capital | 51 to 100 | 2021 |
| Allink Biotherapeutics | Allink Biotherapeutics develops multi-specific antibodies for treating cancer and immune disorders. | Biotech | Series A | $47.0M | 2025-12-16 | $89.0M | Legend Capital, Gaorong Capital, BioVenture +2 | 11 to 50 | 2023 |
| Phrontline Biopharma | Phrontline Biopharma develops antibody-drug conjugate products to treat cancer. | Biotech | Seed | $60.0M | 2025-11-21 | $73.8M | Decheng Capital, Med-Fine Capital | 11 to 50 | 2022 |
| Brise Pharma | Brise Pharma provides scientific research and technical services in the pharmaceutical field. | Biotech | Series A | $28.1M | 2025-11-11 | $228.3M | Qiming Venture Partners, Sherpa Healthcare Partners, BioTrack Capital +1 | 11 to 50 | 2021 |
| GRIT Biotechnology | GRIT Biotechnology develops tumor infiltrating lymphocyte immunotherapy for solid tumors. | Biotech | Series C | $84.0M | 2025-10-14 | $153.5M | Matrix Partners China, Hillhouse Investment, CICC +2 | 51 to 100 | 2019 |
| Meiyou Technology | Meiyou Technology develops DNA synthesizers using enzymatic technology for long-fragment DNA synthesis and splicing. | Biotech | Angel | $1.4M | 2024-06-28 | MiraclePlus, Linear Capital, Danen Capital | 11 to 50 | 2023 |
Table 1. Health care startups in Shanghai, China: the 15 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 447.
Largest rounds
Last 12 months| # | Company | What they do | Sector | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | CORXEL Pharmaceuticals | CORXEL Pharmaceuticals develops medicines for underserved patients. | Biotech | Series D | $287.0M | 2026-01-22 | $451.8M | Leaps by Bayer, RTW Investments | 51 to 100 | 2019 |
| 2 | Full-Life Technologies | Full-Life Technologies develops, produces, and commercializes medicines for cancer therapy. | Biotech | Series D | $109.0M | 2026-05-18 | $337.3M | Sky9 Capital, Chengwei Capital, Prosperity7 Ventures +1 | 51 to 100 | 2021 |
| 3 | Bluesail Surgical | Bluesail Surgical develops surgical instruments for cardiovascular treatments. | Biotech | Series B | $104.5M | 2026-09-23 | $245.4M | Huagai Capital, Linkong Private Equity Fund Management, Linqu County High-Tech Industrial Investment | 101 to 250 | 2020 |
| 4 | Phrontline Biopharma | Phrontline Biopharma develops antibody-drug conjugate products to treat cancer. | Biotech | Seed | $60.0M | 2025-11-21 | $73.8M | Decheng Capital, Med-Fine Capital | 11 to 50 | 2022 |
| 5 | Bivision | Bivision researches and develops targeted radiopharmaceuticals for therapy. | Biotech | Series B | $58.8M | 2026-05-18 | $100.9M | Gaorong Capital, Kaitai Capital, Lichen Capital | 11 to 50 | 2021 |
| 6 | MindRank AI | MindRank AI develops artificial intelligence platforms to discover and develop small molecule drugs. | Artificial intelligence | Series B | $52.0M | 2026-07-08 | $101.0M | Green Pine Capital Partners, Huagai Capital, Sherpa Healthcare Partners +1 | 11 to 50 | 2020 |
| 7 | Allink Biotherapeutics | Allink Biotherapeutics develops multi-specific antibodies for treating cancer and immune disorders. | Biotech | Series A | $47.0M | 2025-12-16 | $89.0M | Legend Capital, Gaorong Capital, BioVenture +2 | 11 to 50 | 2023 |
| 8 | Novamab | Novamab researches and develops new nanobodies. | Biotech | Series B | $43.9M | 2026-04-24 | $97.8M | Qiming Venture Partners, Taiyu Investment, Fuho Capital +1 | 51 to 100 | 2017 |
| 9 | Nutshell Therapeutics | Nutshell Therapeutics discovers small-molecule drugs using insights from protein dynamics. | Artificial intelligence | Series C | $40.0M | 2026-09-15 | $75.2M | Matrix Partners China, Source Code Capital, Northern Light Venture Capital +1 | 51 to 100 | 2013 |
| 10 | Degron Therapeutics | Degron Therapeutics discovers molecular glue degraders for cancer treatment. | Biotech | Series A | $40.0M | 2026-05-14 | $94.0M | Baidu Ventures, BioVenture, New Alliance Capital +2 | 101 to 250 | 2021 |
Table 2. Health care startups in Shanghai, China: the 10 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most active investors
By companies backed| # | Investor | Type | Location | Companies | Share | Funded, 12 months | Latest |
|---|---|---|---|---|---|---|---|
| 1 | Sherpa Healthcare Partners | Venture capital firm | Beijing, China | 7 | 2% | 1 | MindRank AI |
| 2 | Matrix Partners China | Venture capital firm | Beijing, China | 6 | 1% | 2 | Nutshell Therapeutics, Alioth |
| 3 | Qiming Venture Partners | Venture capital firm | Shanghai, China | 5 | 1% | 1 | Novamab |
| 4 | Taiyu Investment | Venture capital firm | Beijing, China | 5 | 1% | 1 | Novamab |
| 5 | BioVenture | Venture capital firm | Suzhou, China | 4 | 1% | 2 | Degron Therapeutics, Allink Biotherapeutics |
| 6 | Northern Light Venture Capital | Venture capital firm | Beijing, China | 4 | 1% | 1 | Nutshell Therapeutics |
| 7 | Baidu Ventures | Venture capital firm | Beijing, China | 3 | 1% | 2 | Nutshell Therapeutics, Degron Therapeutics |
| 8 | Med-Fine Capital | Venture capital firm | Shanghai, China | 3 | 1% | 2 | Degron Therapeutics, Phrontline Biopharma |
| 9 | Gaorong Capital | Venture capital firm | Wangjing, China | 3 | 1% | 2 | Bivision, Allink Biotherapeutics |
| 10 | Legend Capital | Venture capital firm | Beijing, China | 3 | 1% | 2 | Alioth, Allink Biotherapeutics |
| 11 | CICC | Investment bank | Beijing, China | 3 | 1% | 1 | Etern |
| 12 | BioTrack Capital | Venture capital firm | Shanghai, China | 3 | 1% | ||
| 13 | Lilly Asia Ventures | Venture capital firm | Shanghai, China | 3 | 1% | ||
| 14 | SOSV | Venture capital firm | Princeton, United States | 3 | 1% | ||
| 15 | Luminous Ventures (former Lightspeed China Partners) | Venture capital firm | Shanghai, China | 2 | 0% | 1 | Enjosim |
Table 3. Health care startups in Shanghai, China: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Sectors
| Sectors | Companies | Share | Total raised |
|---|---|---|---|
| Biotech | 194 | 43% | $7.3B |
| Software | 50 | 11% | $561.6M |
| Hardware | 17 | 4% | $53.5M |
| Artificial intelligence | 13 | 3% | $378.7M |
| Commerce | 12 | 3% | $30.6M |
| Fintech | 11 | 2% | $1.2B |
| Education | 5 | 1% | $40.7M |
| Cybersecurity | 2 | 0% | |
| Energy | 2 | 0% |
Table 4. Health care startups in Shanghai, China by sector. Source: FundingWatcher. Data as of 16 November 2026.
Funding stage
Table 5. Health care startups in Shanghai, China by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Rounds by month
| Rounds by month | Companies | Share | Raised |
|---|---|---|---|
| November 2026 | 6 | 9% | $99.7M |
| October 2026 | 1 | 1% | $105.0M |
| September 2026 | 5 | 7% | $266.0M |
| August 2026 | 3 | 4% | $1.5M |
| July 2026 | 8 | 11% | $297.3M |
| June 2026 | 1 | 1% | |
| May 2026 | 9 | 13% | $288.8M |
| April 2026 | 5 | 7% | $159.9M |
| March 2026 | 6 | 9% | $35.9M |
| February 2026 | 3 | 4% | $23.0M |
| January 2026 | 10 | 14% | $365.6M |
| December 2025 | 11 | 16% | $140.2M |
| November 2025 | 2 | 3% | $60.0M |
Table 6. Health care startups in Shanghai, China: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most recent round by year
| Most recent round by year | Companies | Share | Raised |
|---|---|---|---|
| 2026 | 57 | 13% | $1.6B |
| 2025 | 66 | 15% | $1.0B |
| 2024 | 31 | 7% | $263.5M |
| 2023 | 36 | 8% | $344.2M |
| 2022 | 35 | 8% | $764.5M |
| 2021 | 60 | 13% | $2.1B |
Table 7. Health care startups in Shanghai, China by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Founding year
| Founding year | Companies | Share |
|---|---|---|
| 2023 or later | 26 | 6% |
| 2020 to 2022 | 98 | 22% |
| 2015 to 2019 | 161 | 37% |
| 2010 to 2014 | 110 | 25% |
| Before 2010 | 46 | 10% |
Table 8. Health care startups in Shanghai, China by founding year. Source: FundingWatcher. Data as of 16 November 2026.
Team size
| Team size | Companies | Share |
|---|---|---|
| 1 to 10 | 48 | 13% |
| 11 to 50 | 129 | 35% |
| 51 to 100 | 69 | 19% |
| 101 to 250 | 53 | 14% |
| 251 to 500 | 31 | 8% |
| 501 to 1,000 | 21 | 6% |
| 1,001 to 5,000 | 11 | 3% |
| 5,001 to 10,000 | 3 | 1% |
| 10,001 or more | 1 | 0% |
Table 9. Health care startups in Shanghai, China by headcount. Source: FundingWatcher. Data as of 16 November 2026.
Method
- A company is on this list when Health care is one of its sectors and its headquarters is in Shanghai, China. On 16 November 2026 that is 447 companies.
- Stage, round, amount and date are those of the company's most recent funding round. Amounts are in US dollars as the source records them.
- The table prints the 15 newest rounds whose row is complete: a one-sentence description, a city, a named fund and an amount. The CSV carries all 447 rows: 158 have no round amount, 0 no city and 166 no website. The CSV carries domain, website, LinkedIn and the cached description sentence where present.
Sources, fields and exclusions of both files: Method.
Questions
- How many health care startups in Shanghai, China are on the list?
- 447, in the file dated 16 November 2026. 70 of them closed their most recent round in the last 12 months.
- What does the CSV contain?
- One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
- How much does the list cost?
- $29 one-time for all 447 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $199.
- What arrives after payment?
- At once: the CSV download link, on the page after payment and by mail.
- Can I see rows before buying?
- The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
- How current is the data?
- The file is dated 16 November 2026. The download link serves the current file each time it is opened.
Not sure about the data?
Download a free 10-row sample first. No account, no payment.